Navigation Links
Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
Date:7/16/2008

SOUTH SAN FRANCISCO, Calif., July 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Tuesday, July 29, 2008 at 4:30 p.m. (Eastern Time) to discuss second quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CEO of Monogram.

To participate in the live teleconference, please call (877) 675-4748, or (719) 325-4848 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Following the live broadcast, a replay of the call will also be available beginning at 9:30 p.m. (Eastern Time) at (888) 203-1112, or (719) 457-0820 for international callers, until 11:59 p.m. (Eastern Time) on Tuesday, August 12, 2008. The replay passcode is 3249168. Access to live and archived audio of the conference call will be available by following the appropriate links at http://www.monogrambio.com and clicking on the Investor Relations link.

The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
2. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
3. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
4. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
5. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
7. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
8. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
9. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
10. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
11. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Now in ... leaders from around the globe to discuss pain management, preclinical and clinical development of new ... Minneapolis, MN ... Summit , set to take place on October 4th-5th, 2010 in Philadelphia, has been announced., ...
... CAMBRIDGE, England , May 25, 2010 Executives ... announced today,an extension of the agreement under which O2h provides multi-FTE -synthetic,chemistry ... , , ... Head of Chemistry said, "We are happy to have signed,this new contract ...
... EXTON, Pa. , May 25 Fibrocell Science, ... the development of autologous cell therapies for aesthetic, medical and ... with Irish Voice newspaper and ... and Chief Financial Officer Declan Daly as a ...
Cached Biology Technology:Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.'s Declan Daly as 'Irish Life Science 50' Member 2
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... our way out of ageing," says Nancy Ross, a McGill geography ... maybe some hearing loss, maybe lose some mobility ageing is ... lead author of a new study about how socio-economic and educational ... a lifetime. "My research looks at how poverty ...
... type of gorilla will receive a helping hand from Newman,s ... $150,000 grant to help save the Grauer,s gorilla in the ... The grant will help equip and support park rangers (or ... National Park, a World Heritage site that is now threatened ...
... This press release is available in German . ... diseases: the minute soot particles from the exhaust gas of ... In order to nevertheless keep the harmful effects to one,s ... for diesel soot have been lowered drastically step by step, ...
Cached Biology News:Lifelong gap in health between rich and poor set by age 20 2Wildlife Conservation Society receives $150,000 grant from Newman's Own Foundation to save gorillas 2Pan-European research project for clean air 2Pan-European research project for clean air 3
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Biology Products: